Best of ASCO - 2014 Annual Meeting

 

Welcome

Small Cell Lung Cancer

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A novel mutation panel for predicting etoposide in small cell lung cancer.

Peng Luo

e20090

A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).

Taofeek Kunle Owonikoko

8515

Assessment of PD-L1 expression and oncogenic gene status in patients with small-cell lung cancer: Immuno-oncology biomarker study in LC-SCRUM-Japan.

Satoshi Oizumi

8558

BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response—Preliminary results from the SCLC cohort.

Rieke Nila Fischer

8563

Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.

Sehhoon Park

8514

Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.

Ippokratis Messaritakis

e20086

Clinical observation of low-dose apatinib in the treatment of small cell lung cancer with antidiuretic hormone secretion.

Yuming Jia

e20087

Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive small cell lung cancer in China.

Lingyu Li

e20083

Defining the role of RUNX1T1 in "combined" small cell lung cancer.

Tian He

e20101

Development of a prognostic risk model for small cell lung cancer: Identification of high-, intermediate-, and low-risk cohorts based on clinical-genomic data.

Fatemeh Ardeshir-Larijani

8554

Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan.

Lowell L. Hart

8505

Efficacy and safety of apatinib in extensive stage small cell lung cancer patients failed from two or more lines of chemotherapy.

Yutao Liu

8553

Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.

Luis G. Paz-Ares

8506

Exploring sex differences in small cell lung cancer: Is this a hormonal issue?

Narjust Duma

e20077

Gene expression profiling of T-cell inflammation in small cell lung cancer.

Gareth Rivalland

e20097

Identifying small cell lung cancer resistance mechanisms to cytotoxic T cells in vitro using whole genome CRISPR screening.

Joseph Hiatt

e20075

Impact of large-scale nationwide genomic screening project for small cell lung cancer (LC-SCRUM-Japan).

Naoki Furuya

8559

KMT2C mutation associated with tumor mutational burden in small cell lung cancer.

Weiguang Gu

e20098

Multicenter phase II trial of RRx-001 in previously treated SCLC.

Daniel Morgensztern

e20104

Nationwide shift in patterns of prophylactic cranial irradiation utilization for extensive-stage small cell lung cancer patients.

Olsi Gjyshi

e20099

NRG Oncology CC003: A randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer.

Vinai Gondi

TPS8578

Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.

Jyoti Malhotra

8516

Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).

Lauren Averett Byers

TPS8576

Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).

Marie-Anne Damiette Smit

TPS8577

Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).

Hiroaki Akamatsu

8557

Phase II study of consolidation amrubicin after concurrent chemoradiotherapy for patients with limited-stage small cell lung cancer.

Hironori Yoshida

8555

Phase II trial of carfilzomib and irinotecan in relapsed small cell lung cancer (NCT01941316).

Susanne M. Arnold

8513

Predictors associated with development of pleural and pericardial effusions in patients with small cell lung cancer treated with third-line therapy.

Rui Jiang

e20088

Preliminary study of S-1 maintenance therapy in extensive stage small-cell lung cancer.

Keke Nie

e20080

Prognostic impact of paraneoplastic syndromes in patients with small cell lung cancer, real-world data.

Gabrielle Picard Leblanc

e20082

Proteomics analysis discovers biomarkers in serum months to years before small cell lung cancer: The HUNT study.

Olav Toai Duc Nguyen

e20095

Quantifying EpCAM heterogeneity of circulating-tumor-cells (CTCs) from small cell lung cancer (SCLC) patients.

Hadas Sorotsky

e20091

Radiologic imaging utilization of small cell lung cancer staging and treatment.

Elias Kikano

e20079

Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer.

Wei-Chu Victoria Lai

8556

RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer—Preliminary findings from part 1 dose-defining phase.

Luis G. Paz-Ares

8562

Single agent immunotherapy for relapsed or refractory small cell lung cancer (rrSCLC).

Ankur Singh

e20094

Thoracic radiotherapy in a cohort study of patients with metastatic small-cell lung neoplasms.

Anabel Mañes

e20093

Thoracic twice-daily radiotherapy and brain metastasis in patients with small cell lung cancer.

Haiyan Zeng

8560

Timing of chemotherapy in small cell lung cancer: A National Cancer Database analysis.

Shruti Bhandari

e20076